1. Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629–55.

   Article  Google Scholar 

2. World Health Organization. Ten threats to global health in 2019. Available at:https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019. Accessed 19 Oct 2024.

3. Godeux A-S, Svedholm E, Barreto S, et al. Interbacterial transfer of carbapenem resistance and large antibiotic resistance islands by natural transformation in pathogenicAcinetobacter. MBio. 2022;13(1): e0263121.

   Article PubMed  Google Scholar 

4. Center for Disease Control. Antimicrobial Resistance Threats in the United States, 2021-2022. 2024.

5. World Health Organization. WHO bacterial priority pathogens list, 2024: Bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance. Available at:https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed.

6. Tamma PD, Heil EL, Justo JA, Mathers AJ, Satlin MJ, Bonomo RA. Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections. Clin Infect Dis 2024:ciae403.

7. Seifert H, Dijkshoorn L, Gerner-Smidt P, Pelzer N, Tjernberg I, Vaneechoutte M. Distribution ofAcinetobacter species on human skin: comparison of phenotypic and genotypic identification methods. J Clin Microbiol. 1997;35(11):2819–25.

   Article CAS PubMed PubMed Central  Google Scholar 

8. Peleg AY, Seifert H, Paterson DL.Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev. 2008;21(3):538–82.

   Article CAS PubMed PubMed Central  Google Scholar 

9. Nemec A. Classification and nomenclature of species in the genusAcinetobacter. Available at:https://szu.cz/wp-content/uploads/2023/10/Classification.pdf. Accessed 19 Oct 2024.

10. Jawad A, Seifert H, Snelling AM, Heritage J, Hawkey PM. Survival ofAcinetobacter baumannii on dry surfaces: comparison of outbreak and sporadic isolates. J Clin Microbiol. 1998;36(7):1938–41.

    Article CAS PubMed PubMed Central  Google Scholar 

11. Fitzpatrick MA, Ozer E, Bolon MK, Hauser AR. Influence of ACB complex genospecies on clinical outcomes in a U.S. hospital with high rates of multidrug resistance. J Infect. 2015;70(2):144–52.

    Article PubMed  Google Scholar 

12. Chuang YC, Sheng WH, Li SY, et al. Influence of genospecies ofAcinetobacter baumannii complex on clinical outcomes of patients withAcinetobacter bacteremia. Clin Infect Dis. 2011;52(3):352–60.

    Article PubMed  Google Scholar 

13. Sedo O, Nemec A, Krizova L, Kacalova M, Zdrahal Z. Improvement of MALDI-TOF MS profiling for the differentiation of species within theAcinetobacter calcoaceticus-Acinetobacter baumannii complex. Syst Appl Microbiol. 2013;36(8):572–8.

    Article CAS PubMed  Google Scholar 

14. Toh BE, Paterson DL, Kamolvit W, et al. Species identification withinAcinetobacter calcoaceticus-baumannii complex using MALDI-TOF MS. J Microbiol Methods. 2015;118:128–32.

    Article CAS PubMed  Google Scholar 

15. Iovleva A, Mustapha MM, Griffith MP, et al. Carbapenem-resistantAcinetobacter baumannii in U.S. Hospitals: diversification of circulating lineages and antimicrobial resistance. MBio. 2022;13(2): e0275921.

    Article PubMed  Google Scholar 

16. Wang M, Ge L, Chen L, et al. Clinical outcomes and bacterial characteristics of carbapenem-resistantAcinetobacter baumannii among patients from different global regions. Clin Infect Dis. 2024;78(2):248–58.

    Article CAS PubMed  Google Scholar 

17. Wong D, Nielsen TB, Bonomo RA, Pantapalangkoor P, Luna B, Spellberg B. Clinical and pathophysiological overview ofAcinetobacter infections: a century of challenges. Clin Microbiol Rev. 2017;30(1):409–47.

    Article CAS PubMed  Google Scholar 

18. Smoke SM, Brophy A, Reveron S, et al. Evolution and transmission of cefiderocol-resistantAcinetobacter baumannii during an outbreak in the burn intensive care unit. Clin Infect Dis. 2023;76(3):e1261–5.

    Article PubMed  Google Scholar 

19. Corcione S, Lupia T, De Rosa FG, Microbiota Interaction Study Group of the European Society of Clinical M, Infectious D. Microbiome in the setting of burn patients: implications for infections and clinical outcomes. Burns Trauma. 2020;8:tkaa033.

    Article PubMed PubMed Central  Google Scholar 

20. Munoz-Price LS. Long-term acute care hospitals. Clin Infect Dis. 2009;49(3):438–43.

    Article PubMed  Google Scholar 

21. Calix JJ, de Almeida MCS, Potter RF, Wallace MA, Burnham CD, Dantas G. Outpatient clonal propagation and rapid regional establishment of an emergent carbapenem-resistantAcinetobacter baumannnii lineage sequence type 499Pas. J Infect Dis. 2023;227(5):631–40.

    Article PubMed  Google Scholar 

22. Harris AD, Pineles L, Johnson JK, et al. Prevalence ofAcinetobacter baumannii andCandida auris in patients receiving mechanical ventilation. JAMA. 2023;330(18):1769–72.

    Article PubMed PubMed Central  Google Scholar 

23. Centers for Disease Control and Prevention. Acinetobacter baumannii infections among patients at military medical facilities treating injured U.S. service members, 2002–2004. MMWR Morbidity Mortality Wkly Rep. 2004;53(45):1063–6.

    Google Scholar 

24. Scott P, Deye G, Srinivasan A, et al. An outbreak of multidrug-resistantAcinetobacter baumannii-calcoaceticus complex infection in the US military health care system associated with military operations in Iraq. Clin Infect Dis. 2007;44(12):1577–84.

    Article CAS PubMed  Google Scholar 

25. Rafei R, Dabboussi F, Hamze M, et al. First report ofbla_NDM-1-producingAcinetobacter baumannii isolated in Lebanon from civilians wounded during the Syrian war. Int J Infect Dis. 2014;21:21–3.

    Article CAS PubMed  Google Scholar 

26. Teicher CL, Ronat JB, Fakhri RM, et al. Antimicrobial drug-resistant bacteria isolated from Syrian war-injured patients, August 2011-March 2013. Emerg Infect Dis. 2014;20(11):1949–51.

    Article CAS PubMed PubMed Central  Google Scholar 

27. Ljungquist O, Nazarchuk O, Kahlmeter G, et al. Highly multidrug-resistant Gram-negative bacterial infections in war victims in Ukraine, 2022. Lancet Infect Dis. 2023;23(7):784–6.

    Article CAS PubMed  Google Scholar 

28. Higgins PG, Hagen RM, Podbielski A, Frickmann H, Warnke P. Molecular epidemiology of carbapenem-resistantAcinetobacter baumannii isolated from war-injured patients from the Eastern Ukraine. Antibiotics (Basel). 2020;9(9):579.

    Article CAS PubMed  Google Scholar 

29. Centers for Disease Control and Prevention. 2022 Special Report: COVID-19 U.S. Impact on Antimicrobial Resistance. Available at:https://www.cdc.gov/drugresistance/pdf/covid19-impact-report-508.pdf. Accessed 19 Oct 2024.

30. Pourajam S, Kalantari E, Talebzadeh H, et al. Secondary bacterial infection and clinical characteristics in patients with COVID-19 admitted to two intensive care units of an academic hospital in iran during the first wave of the pandemic. Front Cell Infect Microbiol. 2022;12: 784130.

    Article CAS PubMed PubMed Central  Google Scholar 

31. Rangel K, Chagas TPG, De-Simone SG.Acinetobacter baumannii Infections in Times of COVID-19 Pandemic. Pathogens. 2021;10(8):1006.

    Article CAS PubMed PubMed Central  Google Scholar 

32. Petazzoni G, Bellinzona G, Merla C, et al. The COVID-19 Pandemic Sparked Off a Large-Scale Outbreak of Carbapenem-ResistantAcinetobacter baumannii from the Endemic Strains at an Italian Hospital. Microbiol Spectr. 2023;11(2): e0450522.

    Article PubMed  Google Scholar 

33. Gottesman T, Fedorowsky R, Yerushalmi R, Lellouche J, Nutman A. An outbreak of carbapenem-resistantAcinetobacter baumannii in a COVID-19 dedicated hospital. Infect Prev Pract. 2021;3(1): 100113.

    Article PubMed PubMed Central  Google Scholar 

34. Clancy CJ, Schwartz IS, Kula B, Nguyen MH. Bacterial superinfections among persons with coronavirus disease 2019: a comprehensive review of data from postmortem studies. Open Forum Infect Dis. 2021;8(3):ofab065.

    Article PubMed PubMed Central  Google Scholar 

35. Perez S, Innes GK, Walters MS, et al. Increase in hospital-acquired carbapenem-resistantAcinetobacter baumannii infection and colonization in an acute care hospital during a surge in COVID-19 Admissions - New Jersey, February-July 2020. MMWR Morb Mortal Wkly Rep. 2020;69(48):1827–31.

    Article CAS PubMed PubMed Central  Google Scholar 

36. Langford BJ, Soucy JR, Leung V, et al. Antibiotic resistance associated with the COVID-19 pandemic: a systematic review and meta-analysis. Clin Microbiol Infect. 2023;29(3):302–9.

    Article CAS PubMed PubMed Central  Google Scholar 

37. Dexter C, Murray GL, Paulsen IT, Peleg AY. Community-acquiredAcinetobacter baumannii: clinical characteristics, epidemiology and pathogenesis. Expert Rev Anti Infect Ther. 2015;13(5):567–73.

    Article CAS PubMed  Google Scholar 

38. Riddles T, Judge D. Community-acquired, bacteraemicAcinetobacter Baumannii pneumonia: a retrospective review of cases in Tropical Queensland, Australia. Trop Med Infect Dis. 2023;8(8):419.

    Article PubMed PubMed Central  Google Scholar 

39. Kornelsen V, Kumar A. Update on multidrug resistance efflux pumps inAcinetobacter spp. Antimicrob Agents Chemother. 2021;65(7): e0051421.

    Article PubMed  Google Scholar 

40. Doi Y, Murray GL, Peleg AY.Acinetobacter baumannii: evolution of antimicrobial resistance-treatment options. Semin Respir Crit Care Med. 2015;36(1):85–98.

    Article PubMed PubMed Central  Google Scholar 

41. European Centre for Disease Prevention and Control. Antimicrobial resistance in the EU/EEA (EARS-Net) Annual Epidemiological Report for 2022. Available at:https://www.ecdc.europa.eu/sites/default/files/documents/AER-antimicrobial-resistance.pdf. Accessed 19 Oct 2024.

42. Chen CH, Wu PH, Lu MC, Ho MW, Hsueh PR. Geographic patterns of carbapenem-resistant, multi-drug-resistant and difficult-to-treatAcinetobacter baumannii in the Asia-Pacific region: results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2020. Int J Antimicrob Agents. 2023;61(2): 106707.

    Article CAS PubMed  Google Scholar 

43. Lee YL, Ko WC, Hsueh PR. Geographic patterns ofAcinetobacter baumannii and carbapenem resistance in the Asia-Pacific Region: results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2012–2019. Int J Infect Dis. 2023;127:48–55.

    Article CAS PubMed  Google Scholar 

44. Pan American Health Organization. Magnitude and Trends of Antimicrobial Resistance in Latin America. ReLAVRA 2014, 2015, 2016. Summary Report. Available at:https://www.paho.org/en/documents/magnitude-and-trends-antimicrobial-resistance-latin-america-relavra-2014-2015-2016. Accessed 19 Oct 2024.

45. Noel HR, Petrey JR, Palmer LD. Mobile genetic elements inAcinetobacter antibiotic-resistance acquisition and dissemination. Ann N Y Acad Sci. 2022;1518(1):166–82.

    Article CAS PubMed PubMed Central  Google Scholar 

46. Fournier PE, Vallenet D, Barbe V, et al. Comparative genomics of multidrug resistance inAcinetobacter baumannii. PLoS Genet. 2006;2(1): e7.

    Article PubMed PubMed Central  Google Scholar 

47. Hamidian M, Nigro SJ. Emergence, molecular mechanisms and global spread of carbapenem-resistantAcinetobacter baumannii. Microb Genom 2019; 5(10):e000306.

48. Paul M, Carrara E, Retamar P, et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). Clin Microbiol Infect. 2022;28(4):521–47.

    Article CAS PubMed  Google Scholar 

49. Nation RL, Velkov T, Li J. Colistin and polymyxin B: peas in a pod, or chalk and cheese? Clin Infect Dis. 2014;59(1):88–94.

    Article CAS PubMed PubMed Central  Google Scholar 

50. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis. 2005;40(9):1333–41.

    Article CAS PubMed  Google Scholar 

51. Clinical and Laboratory Standards Institute. Polymyxin Breakpoints forEnterobacterales, Pseudomonas aeruginosa, andAcinetobacter spp. CLSI rationale document MR01, 2020.

52. Eljaaly K, Bidell MR, Gandhi RG, et al. Colistin Nephrotoxicity: Meta-Analysis of Randomized Controlled Trials. Open Forum Infect Dis. 2021;8(2):ofab026.

    Article PubMed PubMed Central  Google Scholar 

53. Velkov T, Thompson PE, Nation RL, Li J. Structure–activity relationships of polymyxin antibiotics. J Med Chem. 2010;53(5):1898–916.

    Article CAS PubMed PubMed Central  Google Scholar 

54. Novović K, Jovčić B. Colistin Resistance inAcinetobacter baumannii: Molecular Mechanisms and Epidemiology. Antibiotics (Basel). 2023;12(3):516.

    Article PubMed  Google Scholar 

55. Lesho E, Yoon EJ, McGann P, et al. Emergence of colistin-resistance in extremely drug-resistantAcinetobacter baumannii containing a novelpmrCAB operon during colistin therapy of wound infections. J Infect Dis. 2013;208(7):1142–51.

    Article CAS PubMed  Google Scholar 

56. Moffatt JH, Harper M, Harrison P, et al. Colistin resistance inAcinetobacter baumannii is mediated by complete loss of lipopolysaccharide production. Antimicrob Agents Chemother. 2010;54(12):4971–7.

    Article CAS PubMed PubMed Central  Google Scholar 

57. Moffatt JH, Harper M, Adler B, Nation RL, Li J, Boyce JD. Insertion sequence ISAba11 is involved in colistin resistance and loss of lipopolysaccharide inAcinetobacter baumannii. Antimicrob Agents Chemother. 2011;55(6):3022–4.

    Article CAS PubMed PubMed Central  Google Scholar 

58. European Committee on Antimicrobial Susceptibility Testing. Recommendations for MIC determination of colistin (polymyxin E) as recommended by the joint CLSI-EUCAST Polymyxin Breakpoints Working Group, 2016.

59. Satlin MJ, Lewis JS, Weinstein MP, et al. Clinical and laboratory standards institute and European Committee on antimicrobial susceptibility testing position statements on polymyxin B and colistin clinical breakpoints. Clin Infect Dis. 2020;71(9):e523–9.

    Article CAS PubMed  Google Scholar 

60. Karvanen M, Malmberg C, Lagerbäck P, Friberg LE, Cars O. Colistin is extensively lost during standardin vitro experimental conditions. Antimicrob Agents Chemother. 2017;61(11):e00857-e917.

    Article CAS PubMed PubMed Central  Google Scholar 

61. Hindler JA, Humphries RM. Colistin MIC variability by method for contemporary clinical isolates of multidrug-resistant Gram-negative bacilli. J Clin Microbiol. 2013;51(6):1678–84.

    Article CAS PubMed PubMed Central  Google Scholar 

62. Sorensen M, Chandler CE, Gardner FM, et al. Rapid microbial identification and colistin resistance detection via MALDI-TOF MS using a novel on-target extraction of membrane lipids. Sci Rep. 2020;10(1):21536.

    Article CAS PubMed PubMed Central  Google Scholar 

63. Cheah SE, Wang J, Nguyen VT, Turnidge JD, Li J, Nation RL. New pharmacokinetic/pharmacodynamic studies of systemically administered colistin againstPseudomonas aeruginosa andAcinetobacter baumannii in mouse thigh and lung infection models: smaller response in lung infection. J Antimicrob Chemother. 2015;70(12):3291–7.

    CAS PubMed  Google Scholar 

64. Garonzik SM, Li J, Thamlikitkul V, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother. 2011;55(7):3284–94.

    Article CAS PubMed PubMed Central  Google Scholar 

65. Nation RL, Garonzik SM, Thamlikitkul V, et al. Dosing guidance for intravenous colistin in critically-ill patients. Clin Infect Dis. 2017;64(5):565–71.

    Article CAS PubMed  Google Scholar 

66. Sorlí L, Luque S, Grau S, et al. Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study. BMC Infect Dis. 2013;13:380.

    Article PubMed PubMed Central  Google Scholar 

67. Horcajada JP, Sorlí L, Luque S, et al. Validation of a colistin plasma concentration breakpoint as a predictor of nephrotoxicity in patients treated with colistin methanesulfonate. Int J Antimicrob Agents. 2016;48(6):725–7.

    Article CAS PubMed  Google Scholar 

68. Tsuji BT, Pogue JM, Zavascki AP, et al. International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy. 2019;39(1):10–39.

    Article PubMed PubMed Central  Google Scholar 

69. Boisson M, Jacobs M, Grégoire N, et al. Comparison of intrapulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and colistin after aerosol delivery and intravenous administration of CMS in critically ill patients. Antimicrob Agents Chemother. 2014;58(12):7331–9.

    Article PubMed PubMed Central  Google Scholar 

70. Heffernan AJ, Sime FB, Lipman J, et al. Intrapulmonary pharmacokinetics of antibiotics used to treat nosocomial pneumonia caused by Gram-negative bacilli: a systematic review. Int J Antimicrob Agents. 2019;53(3):234–45.

    Article CAS PubMed  Google Scholar 

71. Bergen PJ, Li J, Rayner CR, Nation RL. Colistin methanesulfonate is an inactive prodrug of colistin againstPseudomonas aeruginosa. Antimicrob Agents Chemother. 2006;50(6):1953–8.

    Article CAS PubMed PubMed Central  Google Scholar 

72. Li J, Milne RW, Nation RL, Turnidge JD, Smeaton TC, Coulthard K. Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate. J Antimicrob Chemother. 2004;53(5):837–40.

    Article CAS PubMed  Google Scholar 

73. Couet W, Grégoire N, Gobin P, et al. Pharmacokinetics of colistin and colistimethate sodium after a single 80-mg intravenous dose of CMS in young healthy volunteers. Clin Pharmacol Ther. 2011;89(6):875–9.

    Article CAS PubMed  Google Scholar 

74. Sisay M, Hagos B, Edessa D, Tadiwos Y, Mekuria AN. Polymyxin-induced nephrotoxicity and its predictors: a systematic review and meta-analysis of studies conducted using RIFLE criteria of acute kidney injury. Pharmacol Res. 2021;163: 105328.

    Article CAS PubMed  Google Scholar 

75. Oliota AF, Penteado ST, Tonin FS, Fernandez-Llimos F, Sanches AC. Nephrotoxicity prevalence in patients treated with polymyxins: a systematic review with meta-analysis of observational studies. Diagn Microbiol Infect Dis. 2019;94(1):41–9.

    Article CAS PubMed  Google Scholar 

76. Garcia RCL, Rodrigues RD, Garcia ECL, Rigatto MH. Comparison between colistin and polymyxin B in the treatment of bloodstream infections caused by carbapenem-resistantPseudomonas aeruginosa andAcinetobacter baumannii-calcoaceticus Complex. Antibiotics (Basel). 2023;12(8):1317.

    Article CAS PubMed  Google Scholar 

77. Rigatto MH, Oliveira MS, Perdigão-Neto LV, et al. Multicenter prospective cohort study of renal failure in patients treated with colistin versus polymyxin B. Antimicrob Agents Chemother. 2016;60(4):2443–9.

    Article CAS PubMed PubMed Central  Google Scholar 

78. Tuon FF, Rigatto MH, Lopes CK, Kamei LK, Rocha JL, Zavascki AP. Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium. Int J Antimicrob Agents. 2014;43(4):349–52.

    Article CAS PubMed  Google Scholar 

79. Phe K, Lee Y, McDaneld PM, et al. In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy. Antimicrob Agents Chemother. 2014;58(5):2740–6.

    Article PubMed PubMed Central  Google Scholar 

80. Paul M, Daikos GL, Durante-Mangoni E, et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infect Dis. 2018;18(4):391–400.

    Article CAS PubMed  Google Scholar 

81. Kaye KS, Marchaim D, Thamlikitkul V, et al. colistin monotherapy versus combination therapy for carbapenem-resistant organisms. NEJM Evid. 2023;2(1):evidoa2200131.

    Article  Google Scholar 

82. Nutman A, Lellouche J, Temkin E, et al. Colistin plus meropenem for carbapenem-resistant Gram-negative infections: in vitro synergism is not associated with better clinical outcomes. Clin Microbiol Infect. 2020;26(9):1185–91.

    Article CAS PubMed  Google Scholar 

83. Durante-Mangoni E, Signoriello G, Andini R, et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistantAcinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis. 2013;57(3):349–58.

    Article CAS PubMed  Google Scholar 

84. Park HJ, Cho JH, Kim HJ, Han SH, Jeong SH, Byun MK. Colistin monotherapy versus colistin/rifampicin combination therapy in pneumonia caused by colistin-resistantAcinetobacter baumannii: a randomised controlled trial. J Glob Antimicrob Resist. 2019;17:66–71.

    Article PubMed  Google Scholar 

85. Sirijatuphat R, Thamlikitkul V. Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistantAcinetobacter baumannii infections. Antimicrob Agents Chemother. 2014;58(9):5598–601.

    Article PubMed PubMed Central  Google Scholar 

86. Garnacho-Montero J, Amaya-Villar R, Gutiérrez-Pizarraya A, et al. Clinical efficacy and safety of the combination of colistin plus vancomycin for the treatment of severe infections caused by carbapenem-resistantAcinetobacter baumannii. Chemotherapy. 2013;59(3):225–31.

    Article CAS PubMed  Google Scholar 

87. Petrosillo N, Giannella M, Antonelli M, et al. Clinical experience of colistin-glycopeptide combination in critically ill patients infected with Gram-negative bacteria. Antimicrob Agents Chemother. 2014;58(2):851–8.

    Article PubMed PubMed Central  Google Scholar 

88. Vardakas KZ, Voulgaris GL, Samonis G, Falagas ME. Inhaled colistin monotherapy for respiratory tract infections in adults without cystic fibrosis: a systematic review and meta-analysis. Int J Antimicrob Agents. 2018;51(1):1–9.

    Article CAS PubMed  Google Scholar 

89. Jang JY, Kwon HY, Choi EH, Lee WY, Shim H, Bae KS. Efficacy and toxicity of high-dose nebulized colistin for critically ill surgical patients with ventilator-associated pneumonia caused by multidrug-resistantAcinetobacter baumannii. J Crit Care. 2017;40:251–6.

    Article CAS PubMed  Google Scholar 

90. Jung SY, Lee SH, Lee SY, et al. Antimicrobials for the treatment of drug-resistantAcinetobacter baumannii pneumonia in critically ill patients: a systemic review and Bayesian network meta-analysis. Crit Care. 2017;21(1):319.

    Article PubMed PubMed Central  Google Scholar 

91. Liu CY, Ko HK, Fink JB, et al. Size distribution of colistin delivery by different type nebulizers and concentrations during mechanical ventilation. Pharmaceutics. 2019;11(9):459.

    Article CAS PubMed PubMed Central  Google Scholar 

92. Rouby JJ, Zhu Y, Torres A, Rello J, Monsel A. Aerosolized polymyxins for ventilator-associated pneumonia caused by extensive drug resistant Gram-negative bacteria: class, dose and manner should remain the trifecta. Ann Intensive Care. 2022;12(1):97.

    Article CAS PubMed PubMed Central  Google Scholar 

93. Petersen PJ, Jacobus NV, Weiss WJ, Sum PE, Testa RT. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother. 1999;43(4):738–44.

    Article CAS PubMed PubMed Central  Google Scholar 

94. van Ogtrop ML, Andes D, Stamstad TJ, et al. In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria. Antimicrob Agents Chemother. 2000;44(4):943–9.

    Article PubMed PubMed Central  Google Scholar 

95. Noskin GA. Tigecycline: a new glycylcycline for treatment of serious infections. Clin Infect Dis. 2005;41(Suppl 5):S303–14.

    Article CAS PubMed  Google Scholar 

96. Yaghoubi S, Zekiy AO, Krutova M, et al. Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review. Eur J Clin Microbiol Infect Dis. 2022;41(7):1003–22.

    Article CAS PubMed  Google Scholar 

97. Marchaim D, Pogue JM, Tzuman O, et al. Major variation in MICs of tigecycline in Gram-negative bacilli as a function of testing method. J Clin Microbiol. 2014;52(5):1617–21.

    Article PubMed PubMed Central  Google Scholar 

98. Wyeth Pharmaceuticals Inc. Tygacyl (Tigecycline) For Injection. Available at:https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021821s016lbl.pdf. Accessed 19 Oct 2024.

99. Xie J, Roberts JA, Alobaid AS, et al. Population pharmacokinetics of tigecycline in critically ill patients with severe infections. Antimicrob Agents Chemother. 2017;61(8):e00345-e417.

    Article CAS PubMed PubMed Central  Google Scholar 

100. Muralidharan G, Micalizzi M, Speth J, Raible D, Troy S. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother. 2005;49(1):220–9.

     Article CAS PubMed PubMed Central  Google Scholar 

101. Kim NH, Hwang JH, Song KH, et al. Tigecycline in carbapenem-resistantAcinetobacter baumannii bacteraemia: susceptibility and clinical outcome. Scand J Infect Dis. 2013;45(4):315–9.

     Article CAS PubMed  Google Scholar 

102. Burkhardt O, Rauch K, Kaever V, Hadem J, Kielstein JT, Welte T. Tigecycline possibly underdosed for the treatment of pneumonia: a pharmacokinetic viewpoint. Int J Antimicrob Agents. 2009;34(1):101–2.

     Article CAS PubMed  Google Scholar 

103. Freire AT, Melnyk V, Kim MJ, et al. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis. 2010;68(2):140–51.

     Article CAS PubMed  Google Scholar 

104. United States Committee on Antimicrobial Susceptibility Testing. FDA Drug Safety Communication: Increased risk of death with Tygacil (tigecycline) compared to other antibiotics used to treat similar infections. Available at:https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-increased-risk-death-tygacil-tigecycline-compared-other-antibiotics. Accessed 19 Oct 2024.

105. Liang CA, Lin YC, Lu PL, Chen HC, Chang HL, Sheu CC. Antibiotic strategies and clinical outcomes in critically ill patients with pneumonia caused by carbapenem-resistantAcinetobacter baumannii. Clin Microbiol Infect. 2018;24(8):908.e1-e7.

     Article CAS PubMed  Google Scholar 

106. Zha L, Pan L, Guo J, French N, Villanueva EV, Tefsen B. Effectiveness and safety of high dose tigecycline for the treatment of severe infections: a systematic review and meta-analysis. Adv Ther. 2020;37(3):1049–64.

     Article CAS PubMed PubMed Central  Google Scholar 

107. De Pascale G, Montini L, Pennisi M, et al. High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria. Crit Care. 2014;18(3):R90.

     Article PubMed PubMed Central  Google Scholar 

108. Dimopoulos G, Almyroudi MP, Kapralos I, et al. Intrapulmonary pharmacokinetics of high doses of tigecycline in patients with ventilator-associated pneumonia. Int J Antimicrob Agents. 2022;59(1): 106487.

     Article CAS PubMed  Google Scholar 

109. Goff DA, Kaye KS. Minocycline: an old drug for a new bug: multidrug-resistantAcinetobacter baumannii. Clin Infect Dis. 2014;59(Suppl 6):S365–6.

     Article CAS PubMed  Google Scholar 

110. Greig SL, Scott LJ. Intravenous minocycline: a review inAcinetobacter Infections. Drugs. 2016;76(15):1467–76.

     Article CAS PubMed  Google Scholar 

111. Lashinsky JN, Henig O, Pogue JM, Kaye KS. Minocycline for the treatment of multidrug and extensively drug-resistantA. baumannii: a review. Infect Dis Ther. 2017;6(2):199–211.

     Article PubMed PubMed Central  Google Scholar 

112. Ritchie DJ, Garavaglia-Wilson A. A review of intravenous minocycline for treatment of multidrug-resistantAcinetobacter infections. Clin Infect Dis. 2014;59(Suppl 6):S374–80.

     Article CAS PubMed  Google Scholar 

113. Fragkou PC, Poulakou G, Blizou A, et al. The Role of Minocycline in the Treatment of Nosocomial Infections Caused by Multidrug, Extensively Drug and Pandrug ResistantAcinetobacter baumannii: A Systematic Review of Clinical Evidence. Microorganisms 2019; 7(6):159.

114. Lodise TP, Van Wart S, Sund ZM, et al. Pharmacokinetic and pharmacodynamic profiling of minocycline for injection following a single infusion in critically ill adults in a phase IV open-label multicenter study (ACUMIN). Antimicrob Agents Chemother 2021; 65(3):e01809-20.

115. Tsakris A, Koumaki V, Dokoumetzidis A. Minocycline susceptibility breakpoints forAcinetobacter baumannii: do we need to re-evaluate them? J Antimicrob Chemother. 2019;74(2):295–7.

     Article CAS PubMed  Google Scholar 

116. Lepak AJ, Trang M, Hammel JP, et al. Development of modernizedAcinetobacter baumannii susceptibility test interpretive criteria for recommended antimicrobial agents using pharmacometric approaches. Antimicrob Agents Chemother. 2023;67(4): e0145222.

     Article CAS PubMed  Google Scholar 

117. Flamm RK, Shortridge D, Castanheira M, Sader HS, Pfaller MA. In vitro activity of minocycline against U.S. Isolates ofAcinetobacter baumannii-Acinetobacter calcoaceticus species complex,Stenotrophomonas maltophilia, andBurkholderia cepacia complex: results from the SENTRY Antimicrobial Surveillance Program, 2014 to 2018. Antimicrob Agents Chemother. 2019;63(11):e01154-e1219.

     Article CAS PubMed PubMed Central  Google Scholar 

118. Morrissey I, Olesky M, Hawser S, et al. In Vitro Activity of Eravacycline against Gram-Negative Bacilli Isolated in Clinical Laboratories Worldwide from 2013 to 2017. Antimicrob Agents Chemother. 2020;64(3):e01699-e1719.

     CAS PubMed PubMed Central  Google Scholar 

119. Seifert H, Stefanik D, Sutcliffe JA, Higgins PG. In-vitro activity of the novel fluorocycline eravacycline against carbapenem non-susceptibleAcinetobacter baumannii. Int J Antimicrob Agents. 2018;51(1):62–4.

     Article CAS PubMed  Google Scholar 

120. Scott CJ, Zhu E, Jayakumar RA, Shan G, Viswesh V. Efficacy of eravacycline versus best previously available therapy for adults with pneumonia due to difficult-to-treat resistant (DTR)Acinetobacter baumannii. Ann Pharmacother. 2022;56(12):1299–307.

     Article CAS PubMed  Google Scholar 

121. Penwell WF, Shapiro AB, Giacobbe RA, et al. Molecular mechanisms of sulbactam antibacterial activity and resistance determinants inAcinetobacter baumannii. Antimicrob Agents Chemother. 2015;59(3):1680–9.

     Article PubMed PubMed Central  Google Scholar 

122. Findlay J, Poirel L, Bouvier M, Nordmann P. In vitro activity of sulbactam-durlobactam against carbapenem-resistantAcinetobacter baumannii and mechanisms of resistance. J Glob Antimicrob Resist. 2022;30:445–50.

     Article CAS PubMed  Google Scholar 

123. Brown RM, Wise R, Andrews JM, Hancox J. Comparative pharmacokinetics and tissue penetration of sulbactam and ampicillin after concurrent intravenous administration. Antimicrob Agents Chemother. 1982;21(4):565–7.

     Article CAS PubMed PubMed Central  Google Scholar 

124. Wise R, Donovan IA, Andrews JM, Drumm J, Bennett S. Penetration of sulbactam and ampicillin into peritoneal fluid. Antimicrob Agents Chemother. 1983;24(2):290–2.

     Article CAS PubMed PubMed Central  Google Scholar 

125. Rodvold KA, Gotfried MH, Isaacs RD, O’Donnell JP, Stone E. Plasma and intrapulmonary concentrations of ETX2514 and sulbactam following intravenous administration of ETX2514SUL to healthy adult subjects. Antimicrob Agents Chemother. 2018;62(11):e01089-e1118.

     Article PubMed PubMed Central  Google Scholar 

126. Clinical and Laboratory Standards Institute. CLSI M100-Ed34: Performance Standards for Antimicrobial Susceptibility Testing. Berwyn, PA, 2024.

127. Fernández-Cuenca F, Tomás M, Caballero-Moyano FJ, Bou G, Pascual Á. Reporting antimicrobial susceptibilities and resistance phenotypes inAcinetobacter spp: a nationwide proficiency study. J Antimicrob Chemother. 2018;73(3):692–7.

     Article PubMed  Google Scholar 

128. Jaruratanasirikul S, Nitchot W, Wongpoowarak W, Samaeng M, Nawakitrangsan M. Population pharmacokinetics and Monte Carlo simulations of sulbactam to optimize dosage regimens in patients with ventilator-associated pneumonia caused byAcinetobacter baumannii. Eur J Pharm Sci. 2019;136: 104940.

     Article CAS PubMed  Google Scholar 

129. McLeod SM, Moussa SH, Hackel MA, Miller AA. In vitro activity of sulbactam-durlobactam against Acinetobacter baumannii-calcoaceticus complex isolates collected globally in 2016 and 2017. Antimicrob Agents Chemother. 2020;64(4):e02534-e2619.

     Article CAS PubMed PubMed Central  Google Scholar 

130. WW, Pogue JM. Sulbactam for Treatment of Carbapenem-ResistantAcinetobacter baumannii. Available at:https://www.contagionlive.com/view/sulbactam-for-treatment-of-carbapenem-resistant-acinetobacter-baumannii. Accessed 19 Oct 2024.

131. Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious diseases society of america 2023 guidance on the treatment of antimicrobial resistant gram-negative infections. Clin Infect Dis 2023:ciad428.

132. Lenhard JR, Smith NM, Bulman ZP, et al. High-dose ampicillin-sulbactam combinations combat polymyxin-resistantAcinetobacter baumannii in a hollow-fiber infection model. Antimicrob Agents Chemother. 2017;61(3):e01268-e1316.

     Article CAS PubMed PubMed Central  Google Scholar 

133. Jaruratanasirikul S, Wongpoowarak W, Aeinlang N, Jullangkoon M. Pharmacodynamics modeling to optimize dosage regimens of sulbactam. Antimicrob Agents Chemother. 2013;57(7):3441–4.

     Article CAS PubMed PubMed Central  Google Scholar 

134. Betrosian AP, Frantzeskaki F, Xanthaki A, Georgiadis G. High-dose ampicillin-sulbactam as an alternative treatment of late-onset VAP from multidrug-resistantAcinetobacter baumannii. Scand J Infect Dis. 2007;39(1):38–43.

     Article CAS PubMed  Google Scholar 

135. Liu J, Shu Y, Zhu F, et al. Comparative efficacy and safety of combination therapy with high-dose sulbactam or colistin with additional antibacterial agents for multiple drug-resistant and extensively drug-resistantAcinetobacter baumannii infections: A systematic review and network meta-analysis. J Glob Antimicrob Resist. 2021;24:136–47.

     Article CAS PubMed  Google Scholar 

136. Fass RJ, Gregory WW, D’Amato RF, Matsen JM, Wright DN, Young LS. In vitro activities of cefoperazone and sulbactam singly and in combination against cefoperazone-resistant members of the family Enterobacteriaceae and nonfermenters. Antimicrob Agents Chemother. 1990;34(11):2256–9.

     Article CAS PubMed PubMed Central  Google Scholar 

137. Zhou Y, Zhang J, Chen Y, et al. Combined PK/PD index may be a more appropriate PK/PD index for cefoperazone/sulbactam againstAcinetobacter baumannii in patients with hospital-acquired pneumonia. Antibiotics (Basel). 2022;11(5):703.

     Article CAS PubMed  Google Scholar 

138. Kogilathota Jagirdhar GS, Rama K, Reddy ST, et al. Efficacy of cefoperazone sulbactam in patients withAcinetobacter Infections: a systematic review of the literature. Antibiotics (Basel). 2023;12(3):582.

     Article CAS PubMed  Google Scholar 

139. Kohira N, West J, Ito A, et al. In Vitro antimicrobial activity of a siderophore cephalosporin, S-649266, against enterobacteriaceae clinical isolates including carbapenem-resistant strains. Antimicrob Agents Chemother. 2016;60(2):729–34.

     Article CAS PubMed PubMed Central  Google Scholar 

140. McCreary EK, Heil EL, Tamma PD. New perspectives on antimicrobial agents: cefiderocol. Antimicrob Agents Chemother. 2021;65(8): e0217120.

     Article PubMed  Google Scholar 

141. Malik S, Kaminski M, Landman D, Quale J. Cefiderocol resistance inAcinetobacter baumannii: roles of beta-lactamases, siderophore receptors, and penicillin binding protein 3. Antimicrob Agents Chemother. 2020;64(11):e01221-e1320.

     Article CAS PubMed PubMed Central  Google Scholar 

142. Poirel L, Sadek M, Nordmann P. Contribution of PER-Type and NDM-type β-lactamases to cefiderocol resistance inAcinetobacter baumannii. Antimicrob Agents Chemother. 2021;65(10): e0087721.

     Article PubMed  Google Scholar 

143. Yamano Y. In Vitro activity of cefiderocol against a broad range of clinically important gram-negative bacteria. Clin Infect Dis. 2019;69(Suppl 7):S544–51.

     Article CAS PubMed PubMed Central  Google Scholar 

144. Simner PJ, Patel R. Cefiderocol antimicrobial susceptibility testing considerations: the Achilles’ Heel of the Trojan Horse? J Clin Microbiol. 2020;59(1):e00951-e1020.

     Article PubMed PubMed Central  Google Scholar 

145. Simner PJ, Palavecino EL, Satlin MJ, et al. Potential of inaccurate cefiderocol susceptibility results: a CLSI AST Subcommittee Advisory. J Clin Microbiol. 2023;61(4): e0160022.

     Article PubMed  Google Scholar 

146. Bassetti M, Echols R, Matsunaga Y, et al. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis. 2021;21(2):226–40.

     Article CAS PubMed  Google Scholar 

147. Falcone M, Tiseo G, Leonildi A, et al. Cefiderocol- compared to colistin-based regimens for the treatment of severe infections caused by carbapenem-resistantAcinetobacter baumannii. Antimicrob Agents Chemother. 2022;66(5): e0214221.

     Article PubMed  Google Scholar 

148. Rando E, Segala FV, Vargas J, et al. Cefiderocol for severe carbapenem-resistantA. baumannii pneumonia: towards the comprehension of its place in therapy. Antibiotics (Basel). 2021;11(1):3.

     Article PubMed  Google Scholar 

149. Sansone P, Giaccari LG, Coppolino F, et al. Cefiderocol for Carbapenem-Resistant Bacteria: Handle with Care! A Review of the Real-World Evidence. Antibiotics (Basel). 2022;11(7):904.

     Article CAS PubMed  Google Scholar 

150. Bavaro DF, Papagni R, Belati A, et al. Cefiderocol versus colistin for the treatment of carbapenem-resistantAcinetobacter baumannii complex bloodstream infections: a retrospective, propensity-score adjusted, monocentric cohort study. Infect Dis Ther. 2023;12(8):2147–63.

     Article PubMed PubMed Central  Google Scholar 

151. Russo A, Bruni A, Gullì S, et al. Efficacy of cefiderocol- vs colistin-containing regimen for treatment of bacteraemic ventilator-associated pneumonia caused by carbapenem-resistantAcinetobacter baumannii in patients with COVID-19. Int J Antimicrob Agents. 2023;62(1): 106825.

     Article CAS PubMed PubMed Central  Google Scholar 

152. Gatti M, Cosentino F, Giannella M, Viale P, Pea F. Clinical efficacy of cefiderocol-based regimens in patients with carbapenem-resistantAcinetobacter baumannii infections: A systematic review with meta-analysis. Int J Antimicrob Agents. 2024;63(2): 107047.

     Article CAS PubMed  Google Scholar 

153. Shionogi Inc. Shionogi, GARDP and CHAI announce landmark license and collaboration agreements to treat bacterial infections by expanding access to cefiderocol in 135 countries. Available at:https://gardp.org/shionogi-gardp-and-chai-announce-landmark-license-and-collaboration-agreements-to-treat-bacterial-infections-by-expanding-access-to-cefiderocol-in-135-countries/. Accessed 19 Oct 2024.

154. Paterson DL. Antibacterial agents active against Gram Negative Bacilli in phase I, II, or III clinical trials. Expert Opin Investig Drugs. 2024;33(4):371–87.

     Article CAS PubMed  Google Scholar 

155. Wang M, Ge L, Chen L, et al. Clinical Outcomes and bacterial characteristics of carbapenem-resistantAcinetobacter baumannii among patients from different global regions. Clin Infect Dis. 2023;78(2):248–58.

     Article PubMed Central  Google Scholar 

156. Kaye KS, Shorr AF, Wunderink RG, et al. Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused byAcinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK). Lancet Infect Dis. 2023;23(9):1072–84.

     Article CAS PubMed  Google Scholar 

157. U.S. Food and Drug Administration. Sulbactam and Durlobactam Injection. Available at:https://www.fda.gov/drugs/development-resources/sulbactam-and-durlobactam-injection. Accessed 19 Oct 2024.

158. Iovleva A, McElheny CL, Fowler EL, et al. In vitro activity of sulbactam-durlobactam against colistin-resistant and/or cefiderocol-non-susceptible, carbapenem-resistant Acinetobacter baumannii collected in U.S. hospitals. Antimicrob Agents Chemother. 2024;68(3): e0125823.

     Article PubMed  Google Scholar 

159. Miller AA, Moussa SH, McLeod SM. Characterization ofAcinetobacter baumannii-calcoaceticus complex isolates and microbiological outcome for patients treated with sulbactam-durlobactam in a phase 3 trial (ATTACK). Antimicrob Agents Chemother. 2024;68(5): e0169823.

     Article PubMed  Google Scholar 

160. World Health Organization. WHO publishes list of bacteria for which new antibiotics are urgently needed. Available at:https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed. Accessed 19 Oct 2024.

161. Isler B, Doi Y, Bonomo RA, Paterson DL. New treatment options against carbapenem-resistantAcinetobacter baumannii Infections. Antimicrob Agents Chemother. 2019;63(1):e01110-18.

     Article PubMed  Google Scholar 

162. Moya B, Barcelo IM, Bhagwat S, et al. Potent β-lactam enhancer activity of Zidebactam and WCK 5153 againstAcinetobacter baumannii, including carbapenemase-producing clinical isolates. Antimicrob Agents Chemother. 2017;61(11):e01238-e1317.

     Article CAS PubMed PubMed Central  Google Scholar 

163. Sun D, Tsivkovski R, Pogliano J, et al. Intrinsic antibacterial activity of xeruborbactam in vitro: assessing spectrum and mode of action. Antimicrob Agents Chemother. 2022;66(10): e0087922.

     Article PubMed  Google Scholar 

164. Fratoni AJ, Berry AV, Liu X, et al. Imipenem/funobactam (formerly XNW4107) in vivo pharmacodynamics against serine carbapenemase-producing Gram-negative bacteria: a novel modelling approach for time-dependent killing. J Antimicrob Chemother. 2023;78(9):2343–53.

     Article CAS PubMed PubMed Central  Google Scholar 

165. Li Y, Yan M, Xue F, et al. In vitro and in vivo activities of a novel β-lactamase inhibitor combination imipenem/XNW4107 against recent clinical Gram-negative bacilli from China. J Glob Antimicrob Resist. 2022;31:1–9.

     Article CAS PubMed  Google Scholar 

166. Davies DT, Leiris S, Zalacain M, et al. Discovery of ANT3310, a novel broad-spectrum serine β-lactamase inhibitor of the diazabicyclooctane class, which strongly potentiates meropenem activity against carbapenem-resistantEnterobacterales andAcinetobacter baumannii. J Med Chem. 2020;63(24):15802–20.

     Article CAS PubMed  Google Scholar 

167. Sumitomo Pharma. Joint Research between The Kitasato Institute and Sumitomo Pharma: Drug Combination of Meropenem and KSP-1007 for Treatment of Carbapenem-Resistant Bacteria Infections Designated as Qualified Infectious Disease Product (QIDP)/Fast Track. Available at:https://www.sumitomo-pharma.com/news/20220929.html. Accessed 19 Oct 2024.

168. Duncan LR, Wang W, Sader HS. In Vitro Potency and Spectrum of the Novel Polymyxin MRX-8 Tested against Clinical Isolates of Gram-Negative Bacteria. Antimicrob Agents Chemother. 2022;66(5): e0013922.

     Article PubMed  Google Scholar 

169. Rodvold KA, Bader J, Bruss JB, Hamed K. Pharmacokinetics of SPR206 in plasma, pulmonary epithelial lining fluid, and alveolar macrophages following intravenous administration to healthy adult subjects. Antimicrob Agents Chemother. 2023;67(7): e0042623.

     Article PubMed  Google Scholar 

170. Roberts KD, Zhu Y, Azad MAK, et al. A synthetic lipopeptide targeting top-priority multidrug-resistant Gram-negative pathogens. Nat Commun. 2022;13(1):1625.

     Article CAS PubMed PubMed Central  Google Scholar 

171. Lepak AJ, Wang W, Andes DR. Pharmacodynamic evaluation of MRX-8, a novel polymyxin, in the neutropenic mouse thigh and lung infection models against gram-negative pathogens. Antimicrob Agents Chemother. 2020;64(11):e01517-e1520.

     Article CAS PubMed PubMed Central  Google Scholar 

172. Huband MD, Mendes RE, Pfaller MA, et al. In vitro activity of KBP-7072, a novel third-generation tetracycline, against 531 recent geographically diverse and molecularly characterizedAcinetobacter baumannii species complex isolates. Antimicrob Agents Chemother. 2020;64(5):e02375-e2419.

     Article CAS PubMed PubMed Central  Google Scholar 

173. Vakulenko SB, Mobashery S. Versatility of aminoglycosides and prospects for their future. Clin Microbiol Rev. 2003;16(3):430–50.

     Article CAS PubMed PubMed Central  Google Scholar 

174. Becker K, Aranzana-Climent V, Cao S, et al. Efficacy of EBL-1003 (apramycin) againstAcinetobacter baumannii lung infections in mice. Clin Microbiol Infect. 2021;27(9):1315–21.

     Article CAS PubMed  Google Scholar 

175. Quirke JCK, Rajasekaran P, Sarpe VA, et al. Apralogs: apramycin 5-O-glycosides and ethers with improved antibacterial activity and ribosomal selectivity and reduced susceptibility to the aminoacyltranserferase (3)-IV resistance determinant. J Am Chem Soc. 2020;142(1):530–44.

     Article CAS PubMed  Google Scholar 

176. Mann CA, Carvajal Moreno JJ, Lu Y, et al. Novel bacterial topoisomerase inhibitors: unique targeting activities of amide enzyme-binding motifs for tricyclic analogs. Antimicrob Agents Chemother. 2023;67(10): e0048223.

     Article PubMed  Google Scholar 

177. Huband M, Lindley J, Watters A, et al. In Vitro Activity of BWC0977 (a Novel Bacterial Topoisomerase Inhibitor and Comparators against Recent Clinical and Molecularly Characterized Enterobacteriaceae and Non-Fermenter Isolates from the United States and Europe. Available at:https://www.jmilabs.com/data/posters/ECCMID19-BWC0977-activity.pdf?x21206.

178. Trebosc V, Kemmer C, Lociuro S, Gitzinger M, Dale GE. Rifabutin for infusion (BV100) for the treatment of severe carbapenem-resistantAcinetobacter baumannii infections. Drug Discov Today. 2021;26(9):2099–104.

     Article CAS PubMed  Google Scholar 

179. Vinogradov AA, Yin Y, Suga H. Macrocyclic peptides as drug candidates: recent progress and remaining challenges. J Am Chem Soc. 2019;141(10):4167–81.

     Article CAS PubMed  Google Scholar 

180. Dougherty PG, Sahni A, Pei D. Understanding cell penetration of cyclic peptides. Chem Rev. 2019;119(17):10241–87.

     Article CAS PubMed PubMed Central  Google Scholar 

181. Driggers EM, Hale SP, Lee J, Terrett NK. The exploration of macrocycles for drug discovery–an underexploited structural class. Nat Rev Drug Discovery. 2008;7(7):608–24.

     Article CAS PubMed  Google Scholar 

182. Zampaloni C, Mattei P, Bleicher K, et al. A novel antibiotic class targeting the lipopolysaccharide transporter. Nature. 2024;625(7995):566–71.

     Article CAS PubMed PubMed Central  Google Scholar 

183. Guenther A, Millar L, Messer A, et al. 2126. Safety, tolerability, and pharmacokinetics (PK) in healthy participants following single dose administration of zosurabalpin, a novel pathogen-specific antibiotic for the treatment of SeriousAcinetobacter. Infections. 2023;10(Supplement_2):ofad500.1749.

     Google Scholar 

184. He P, Huang S, Wang R, et al. Novel nitroxoline derivative combating resistant bacterial infections through outer membrane disruption and competitive NDM-1 inhibition. Emerg Microbes Infect. 2024;13(1):2294854.

     Article PubMed  Google Scholar 

185. Asieris. APL-2301, a compound developed by Asieris for the treatment ofAcinetobacter baumannii infection, was approved for Phase I clinical trials in Australia. Available at:https://www.prnewswire.com/news-releases/apl-2301-a-compound-developed-by-asieris-for-the-treatment-of-acinetobacter-baumannii-infection-was-approved-for-phase-i-clinical-trials-in-australia-302022122.html. Accessed 19 Oct 2024.

186. Schooley RT, Biswas B, Gill JJ, et al. Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistantAcinetobacter baumannii infection. Antimicrob Agents Chemother. 2017;61(10):e00954-e1017.

     Article CAS PubMed PubMed Central  Google Scholar 

187. LaVergne S, Hamilton T, Biswas B, Kumaraswamy M, Schooley RT, Wooten D. Phage Therapy for a Multidrug-ResistantAcinetobacter baumannii Craniectomy Site Infection. Open Forum Infect Dis. 2018;5(4):ofy064.

     Article PubMed PubMed Central  Google Scholar 

188. Nir-Paz R, Gelman D, Khouri A, et al. Successful treatment of antibiotic-resistant, poly-microbial bone infection with bacteriophages and antibiotics combination. Clin Infect Dis. 2019;69(11):2015–8.

     Article PubMed  Google Scholar 

189. Nir-Paz R, Onallah H, Gellman YN, et al. 1690. Assessing the safety of TP-102 bacteriophage treatment in the management of diabetic foot infections. Open Forum Infect Dis 2022;9(Supplement_2):ofac492.1320.

190. Mahlapuu M, Håkansson J, Ringstad L, Björn C. Antimicrobial peptides: an emerging category of therapeutic agents. Front Cell Infect Microbiol. 2016;6:194.

     Article PubMed PubMed Central  Google Scholar 

191. Huang D, Pachuda N, Sauer JM, Dobbins D, Steckbeck J. The engineered antibiotic peptide PLG0206 eliminates biofilms and is a potential treatment for periprosthetic joint infections. Antibiotics (Basel). 2021;11(1):41.

     Article PubMed  Google Scholar 

192. Huang DB, Brothers KM, Mandell JB, et al. Engineered peptide PLG0206 overcomes limitations of a challenging antimicrobial drug class. PLoS ONE. 2022;17(9): e0274815.

     Article CAS PubMed PubMed Central  Google Scholar 

193. Michaeli J, Mandel S, Maximov S, et al. In Vitro and In Vivo Antimicrobial Activity of the Novel Peptide OMN6 against Multidrug-ResistantAcinetobacter baumannii. Antibiotics (Basel) 2022; 11(9):1201.

194. Rogers JV, Hall VL, McOsker CC. Crumbling the castle: targeting DNABII proteins for collapsing bacterial biofilms as a therapeutic approach to treat disease and combat antimicrobial resistance. Antibiotics (Basel). 2022;11(1):104.

     Article CAS PubMed  Google Scholar 

195. Soliman C, Walduck AK, Yuriev E, et al. Structural basis for antibody targeting of the broadly expressed microbial polysaccharide poly-N-acetylglucosamine. J Biol Chem. 2018;293(14):5079–89.

     Article CAS PubMed PubMed Central  Google Scholar 

Download references